PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

This authorization is the first authorized treatment of a patient with MDMA outside of a clinical trial in Canadian historyVANCOUVER, British Columbia, May 16, 2023 -- PharmAla Biotech Holdings... | May 16, 2023

Related Keywords

Montreal ,Quebec ,Canada ,Australia ,United Kingdom ,Vancouver ,British Columbia ,British ,Canadian ,Alexandre Grenier ,Nick Kadysh ,Nicholas Kadysh ,Access Program ,Neither The Canadian Securities Exchange ,Regulation Services Provider ,Health Canada Controlled Drugs ,Pharmala Biotech Holdings Inc ,Ccrest Laboratories Inc ,Shaman Pharma Corp ,Health Canada Special Access Program ,Health Canada ,Ala Biotech Holdings ,Shaman Pharma ,Special Access ,Special Access Program ,Pharmala Biotech ,Joint Venture ,Laboratories Inc ,Controlled Drugs ,Substances Dealer ,Canadian Securities Exchange ,Pharmala Biotech Holdings Inc Stock Exchange ,News ,Information ,Press Release ,This ,Authorization ,Us ,The ,First ,Uthorized ,Treatment ,F ,Patient ,Ith ,Dma ,Outside ,Linical ,Trial ,N ,Bay ,023 ,Harmala ,Iotech Mdma Ca71719l1067 ,